RecruitingNot applicableNCT04605146
Impact of Telemonitoring for the Management of Side Effects in Patients with Melanoma, Lung or Renal Cancer, Treated with Immunotherapy Combination of Nivolumab and Ipilimumab or Adjuvant Nivolumab Monotherapy
Studying Acquired cystic disease-associated renal cell carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Hospices Civils de Lyon
- Principal Investigator
- Stéphane DALLEDepartment of Dermatology, HCL-Cancer Institute
- Intervention
- Tele-monitoring(behavioral)
- Enrollment
- 100 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2028
Study locations (10)
- Groupement hospitalier Est - Multidisciplinary oncological platform, Bron, France
- Hôpital Louis Pradel - Department of Pneumology, Bron, France
- University hospital of Grenoble Alpes - Department of dermatology, Grenoble, France
- University hospital of Grenoble Alpes - Department of Medical Oncology, Grenoble, France
- Hôpital de la Croix Rousse - Department of Pneumology, Lyon, France
- Hôpital Edouard Herriot - Department of urology, Lyon, France
- Centre Hospitalier Lyon Sud - Department of Medical Oncology, Pierre-Bénite, France
- Hôpital Lyon Sud - Department of Dermatology, HCL-Cancer Institute, Pierre-Bénite, France
- Hôpital Lyon Sud - Department of pneumology,Thoracic oncology, Pierre-Bénite, France
- University hospital of Saint-Etienne - Department of dermatology, Saint-Etienne, France
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04605146 on ClinicalTrials.govOther trials for Acquired cystic disease-associated renal cell carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06882486Post-immunotherapy Nephrectomy for Metastatic Kidney Cancer After Complete or Major Response to Systemic TherapyInstitut Paoli-Calmettes
- RECRUITINGPHASE1NCT07517198Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid TumorsExscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
- RECRUITINGNANCT06907095Cohort Evaluation of Body Fluids Early Detection of Cancer in High-risk IndividualsGustave Roussy, Cancer Campus, Grand Paris
- RECRUITINGNANCT07461090Laparoscopic Versus Open Nephrectomy : Clinical Effectivness and Cost AnalysisMenoufia University
- RECRUITINGPHASE1NCT07195682A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)Bristol-Myers Squibb
- RECRUITINGPHASE1NCT07006688A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal ImpairmentServier Bio-Innovation LLC
- RECRUITINGPHASE1, PHASE2NCT07219576Retifanlimab and Ruxolitinib In Solid MalignanciesUniversity of California, San Diego
- RECRUITINGPHASE1, PHASE2NCT07239596Phase Ib/II Clinical Study of SHR-8068 Combined With Adebrelimab and Other Anti-tumor Drugs in the Treatment of Advanced Renal Cell CarcinomSuzhou Suncadia Biopharmaceuticals Co., Ltd.
See all trials for Acquired cystic disease-associated renal cell carcinoma →